TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ac Immune Sa
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune reported Q3 2025 financial results, highlighting a strategic refocus on high-value neurodegenerative disease assets, reducing workforce by 30%, and maintaining cash resources until Q3 2027. The company is progressing multiple clinical-stage immunotherapy and small molecule programs targeting neurodegenerative diseases.

Insights
DHI   negative

Housing-related stock declined 3.41% due to potential impact of sustained higher borrowing costs


ACIU   neutral

Mixed financial performance with strategic workforce reduction and focused pipeline, reporting a net loss but extending cash runway and maintaining progress on key research programs